These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29219017)

  • 1. Eribulin in advanced breast cancer: safety, efficacy and new perspectives.
    Garrone O; Miraglio E; Vandone AM; Vanella P; Lingua D; Merlano MC
    Future Oncol; 2017 Dec; 13(30):2759-2769. PubMed ID: 29219017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer.
    O'Shaughnessy J; Kaklamani V; Kalinsky K
    Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eribulin mesylate: a novel halichondrin B analogue for the treatment of metastatic breast cancer.
    McBride A; Butler SK
    Am J Health Syst Pharm; 2012 May; 69(9):745-55. PubMed ID: 22517020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eribulin mesylate.
    Jain S; Vahdat LT
    Clin Cancer Res; 2011 Nov; 17(21):6615-22. PubMed ID: 21859830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness and safety of eribulin mesylate: a new therapeutic option in the treatment of metastatic breast cancer.
    O'Sullivan Coyne G; Walsh J; Kelly CM
    Expert Opin Drug Saf; 2012 Jul; 11(4):643-50. PubMed ID: 22694309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eribulin long-term response and rechallenge: report of two clinical cases.
    Barbieri E; Rubino D; Hakim R; Fini A; Lenzi M; Zamagni C
    Future Oncol; 2017 Apr; 13(11s):35-43. PubMed ID: 28481188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review on the clinical use of eribulin mesylate for the treatment of breast cancer.
    Aseyev O; Ribeiro JM; Cardoso F
    Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eribulin mesylate for the treatment of breast cancer.
    Cigler T; Vahdat LT
    Expert Opin Pharmacother; 2010 Jun; 11(9):1587-93. PubMed ID: 20450446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and preclinical features of eribulin-related peripheral neuropathy.
    Tarasiuk O; Cavaletti G; Meregalli C
    Exp Neurol; 2022 Feb; 348():113925. PubMed ID: 34801586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long response to eribulin in breast cancer: a case report.
    Borgonovo K; Petrelli F; Cabiddu M; Ghilardi M; Coinu A; Seghezzi S; Barni S
    Future Oncol; 2015; 11(15 Suppl):3-8. PubMed ID: 26235258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Tumor-infiltrating lymphocytes (TILs) to predict the treatment response to eribulin chemotherapy in breast cancer.
    Kashiwagi S; Asano Y; Goto W; Takada K; Takahashi K; Noda S; Takashima T; Onoda N; Tomita S; Ohsawa M; Hirakawa K; Ohira M
    PLoS One; 2017; 12(2):e0170634. PubMed ID: 28166544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eribulin mesylate in advanced breast cancer: retrospective review of a single institute experience.
    Martella F; Bacci C; Giordano C; Montagnani F; Gelain E; Rabatti L; Fioretto L
    Future Oncol; 2015; 11(15 Suppl):31-6. PubMed ID: 26235263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eribulin mesylate (E7389): review of efficacy and tolerability in breast, pancreatic, head and neck, and non-small cell lung cancer.
    Scarpace SL
    Clin Ther; 2012 Jul; 34(7):1467-73. PubMed ID: 22739019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical efficacy of eribulin mesylate for the treatment of metastatic soft tissue sarcoma.
    Emambux S; Italiano A
    Expert Opin Pharmacother; 2017 Jun; 18(8):819-824. PubMed ID: 28468516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eribulin mesylate in the management of metastatic breast cancer and other solid cancers: a drug review.
    Polastro L; Aftimos PG; Awada A
    Expert Rev Anticancer Ther; 2014 Jun; 14(6):649-65. PubMed ID: 24852360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eribulin efficacy based on type of metastatic site: a real-life study in heavily pretreated metastatic breast cancer.
    Prestifilippo A; Grippaldi D; Blanco G; Memeo L; Puliafito I; Giuffrida D
    Future Oncol; 2017 Apr; 13(11s):5-10. PubMed ID: 28481186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer.
    Mani S; Swami U
    Drugs Today (Barc); 2010 Sep; 46(9):641-53. PubMed ID: 20967296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eribulin in non-small cell lung cancer: challenges and potential strategies.
    Swami U; Shah U; Goel S
    Expert Opin Investig Drugs; 2017 Apr; 26(4):495-508. PubMed ID: 28161993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results.
    Park YH; Kim TY; Im YH; Lee KS; Park IH; Sohn J; Lee SH; Im SA; Kim JH; Kim SH; Lee SJ; Koh SJ; Lee KH; Choi YJ; Cho EK; Lee S; Kang SY; Seo JH; Kim SB; Jung KH
    Cancer Res Treat; 2017 Apr; 49(2):423-429. PubMed ID: 27488876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane.
    Vahdat LT; Pruitt B; Fabian CJ; Rivera RR; Smith DA; Tan-Chiu E; Wright J; Tan AR; Dacosta NA; Chuang E; Smith J; O'Shaughnessy J; Shuster DE; Meneses NL; Chandrawansa K; Fang F; Cole PE; Ashworth S; Blum JL
    J Clin Oncol; 2009 Jun; 27(18):2954-61. PubMed ID: 19349550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.